Drug-induced diarrhea associated with antineoplastic drugs

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Diarrhea is the most common adverse reaction of anticancer drugs, as well as radiation therapy of the pelvic organs or abdominal cavity: the incidence of diarrhea of different seveity reaches 80% during chemotherapy and / or radiation therapy; one third of these patients develop severe diarrhea (3rd or 4th degree). Most often, drug-induced diarrhea occurs during chemotherapy, using 5-fluorouracil or irinotecan, taking new anticancer drugs from the classes of checkpoint inhibitors, monoclonal antibodies, tyrosine kinase inhibitors. The most common mechanisms underlying the development of drug-induced diarrhea are damage to the intestinal mucosa, impaired absorption of proteins, carbohydrates, fats, inflammation, a perverse immune response, microflora imbalance, and others.

Algorithms for the management of patients with severe diarrhea include suspension (grade 1-2, 3) or complete cessation (grade 4, grade 3) of the use of an antineoplastic agent – an inducer, prescribing drugs that reduce intestinal motility (loperamide) while excluding the infectious nature of diarrhea, intravenous methylprednisolone (for example, diarrhea caused by monoclinal antibodies in the absence of suspicion of potential bowel perforation). In cases where drug-induced diarrhea lasts more than 48 hours, or a patient reports symptoms of dehydration, or a fever occurs, urgent hospitalization is necessary.

The objective of this review is to analyze scientific literature data on the prevalence, pathophysiological mechanisms and risk factors for the development of diarrhea associated with the intake of anticancer drugs, as well as its prevention and treatment.

全文:

受限制的访问

作者简介

Dmitry Sychev

Russian Medical Academy of Continuous Professional Education

Email: dimasychev@mail.ru
ORCID iD: 0000-0002-4496-3680
SPIN 代码: 4525-7556

MD, Dr. Sci. (Med.), Professor, Correspondence Member of the RAS, Professor of the RAS

俄罗斯联邦, 2/1 Building 1 Barrikadnaya St., Moscow, 125993

Olga Ostroumova

Russian Medical Academy of Continuous Professional Education; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0002-0795-8225
SPIN 代码: 3910-6585

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 2/1 Building 1 Barrikadnaya St., Moscow, 125993; Moscow

Liliya Ziganshina

Russian Medical Academy of Continuous Professional Education

Email: lezign@gmail.com
ORCID iD: 0000-0003-1999-0705
SPIN 代码: 6061-7223

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 2/1 Building 1 Barrikadnaya St., Moscow, 125993

Anastasiya Filippova

Russian Medical Academy of Continuous Professional Education

编辑信件的主要联系方式.
Email: filippova.96@mail.ru
ORCID iD: 0000-0003-3081-602X

ординатор кафедры терапии и полиморбидной патологии имени академика М.С. Вовси

俄罗斯联邦, 2/1 Building 1 Barrikadnaya St., Moscow, 125993

参考

  1. Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918–2926. doi: 10.1200/JCO.2004.04.132
  2. Sanguineti G, Endres EJ, Parker BC, et al. Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer. Acta Oncol. 2008;47(2):301–310. doi: 10.1080/02841860701558849
  3. Maroun JA, Anthony LB, Blais N, et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol. 2007;14(1):13–20. doi: 10.3747/co.2007.96
  4. Bossi P, Antonuzzo A, Cherny NI, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv126–iv142. doi: 10.1093/annonc/mdy145
  5. Antonuzzo A, Lucchesi M, Brunetti IM, et al. Supportive care and not only palliative care in the route of cancer patients. Support Care Cancer. 2013;21(3):657–658. doi: 10.1007/s00520-012-1658-6
  6. Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15(10):447–460. doi: 10.1016/S1470-2045(14)70006-3
  7. Dunberger G, Lind H, Steineck G, et al. Loose stools lead to fecal incontinence among gynecological cancer survivors. Acta Oncol. 2011;50(2):233–242. doi: 10.3109/0284186X.2010.535013
  8. Dunberger G, Lind H, Steineck G, et al. Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls. Eur J Cancer. 2010;46(3):606–615. doi: 10.1016/j.ejca.2009.10.023
  9. Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract. 2007;13(4):181–198. doi: 10.1177/1078155207077335
  10. Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer. 2006;14(9):890–900. doi: 10.1007/s00520-006-0040-y
  11. Andreyev HJ, Davidson SE, Gillespie C, et al. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut. 2012;61(2):179–192. doi: 10.1136/gutjnl-2011-300563
  12. Wei D, Heus P, van de Wetering FT, et al. Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer. Cochrane Database Syst Rev. 2018;8(8):CD008831. doi: 10.1002/14651858.CD008831.pub3
  13. Miller L. Guidelines for Management of Systemic Anti-Cancer Therapy (SACT) induced diarrhoea in adult haematology and oncology patients [Internet]. Available from: https://www.nhsscotlandnorth.scot/uploads/tinymce/NCA/SACT %20Guidelines/NOS-STG-003_ %20diarrhoea_version %202.pdf. Accessed: Aug 12, 2021.
  14. Common Terminology Criteria for Adverse Events (CTCAE). Version 5 ed. U.S. [Internet]. Department of Health and Human Services. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed: Aug 12, 2021.
  15. Verhaar S, Vissers PA, Maas H, et al. Treatment-related differences in health related quality of life and disease specific symptoms among colon cancer survivors: results from the population-based PROFILES registry. Eur J Cancer. 2015;51(10):1263–1273. doi: 10.1016/j.ejca.2015.04.004
  16. Parnes HL, Fung E, Schiffer CA. Chemotherapy-induced lactose intolerance in adults. Cancer. 1994;74(5):1629–1633. DOI: 10.1002/ 1097-0142(19940901)74:5<1629::aid-cncr2820740523>3.0.co;2-l
  17. Osterlund P, Ruotsalainen T, Peuhkuri K, et al. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol. 2004;2(8):696–703. doi: 10.1016/s1542-3565(04)00293-9
  18. Pearson AD, Craft AW, Pledger JV, et al. Small bowel function in acute lymphoblastic leukaemia. Arch Dis Child. 1984;59(5):460–465. doi: 10.1136/adc.59.5.460
  19. Pettoello-Mantovani M, Guandalini S, diMartino L, et al. Prospective study of lactose absorption during cancer chemotherapy: feasibility of a yogurt-supplemented diet in lactose malabsorbers. J Pediatr Gastroenterol Nutr. 1995;20(2):189–195. doi: 10.1097/00005176-199502000-00009
  20. Bustillo I, Larson H, Saif MW. Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer. JOP. 2009;10(5):576–578.
  21. Stringer AM, Gibson RJ, Logan RM, et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood). 2009;234(4):430–441. doi: 10.3181/0810-RM-301
  22. Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38(7):674–688. doi: 10.1111/apt.12456
  23. Grigg AP, Angus PW, Hoyt R, Szer J. The incidence, pathogenesis and natural history of steatorrhea after bone marrow transplantation. Bone Marrow Transplant. 2003;31(8):701–703. doi: 10.1038/sj.bmt.1703911
  24. Meta-Analysis Group In Cancer, Lévy E, Piedbois P, Buyse M, et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16(11):3537–3541. doi: 10.1200/JCO.1998.16.11.3537
  25. Claassen YH, van der Valk MJ, Breugom AJ, et al. Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. Cochrane Database Syst Rev. 2018;11(11):CD012326. doi: 10.1002/14651858.CD012326.pub2
  26. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18(6):1337–1345. doi: 10.1200/JCO.2000.18.6.1337
  27. Yumuk PF, Aydin SZ, Dane F, et al. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients. Int J Colorectal Dis. 2004;19(6):609–610. doi: 10.1007/s00384-004-0613-5
  28. Tomita Y, Moldovan M, Chang Lee R, et al. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Cochrane Database Syst Rev. 2020;11(11):CD012078. doi: 10.1002/14651858.cd012078.pub2
  29. Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010;24(1):104–123. doi: 10.1002/bmc.1345
  30. Wulaningsih W, Wardhana A, Watkins J, et al. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. Cochrane Database Syst Rev. 2016;2:CD008593. doi: 10.1002/14651858.CD008593.pub3
  31. Clarke SJ, Yip S, Brown C, et al. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. Eur J Cancer. 2011;47(12):1826–1836. doi: 10.1016/j.ejca.2011.04.024
  32. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51–63. doi: 10.1177/1758834009355164
  33. Chen E, Abu-Sbeih H, Thirumurthi S, et al. Clinical characteristics of colitis induced by taxane-based chemotherapy. Ann Gastroenterol. 2020;33(1):59–67. doi: 10.20524/aog.2019.0431
  34. Cherny NI. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage. 2008;36(4):413–423. doi: 10.1016/j.jpainsymman.2007.10.007
  35. Shaikh DH, Baiomi A, Mehershahi S, et al. Paclitaxel-induced bowel perforation: a rare cause of acute abdomen. Case Rep Gastroenterol. 2020;14(3):687–694. doi: 10.1159/000510131
  36. Aapro M, Tjulandin S, Bhar P, Gradishar W. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast. 2011;20(5):468–474. doi: 10.1016/j.breast.2011.07.005
  37. Dranitsaris G, Yu B, King J, et al. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective. Clinicoecon Outcomes Res. 2015;7:249–256. DOI: 10.2147 / CEOR.S82194
  38. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154. doi: 10.1016/S0140-6736(10)61389-X
  39. Nieuweboer AJ, de Graan AM, Hamberg P, et al. Effects of budesonide on cabazitaxel pharmacokinetics and cabazitaxel-induced diarrhea: a randomized, open-label multicenter phase II study. Clin Cancer Res. 2017;23(7):1679–1683. doi: 10.1158/1078-0432.CCR-16-2110
  40. Venkatesh P, Kasi A. Anthracyclines. In: StatPearls. Treasure Island (FL). StatPearls Publishing; 2021.
  41. McQuade RM, Stojanovska V, Abalo R, et al. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol. 2016;7:414. doi: 10.3389/fphar.2016.00414
  42. Pessi MA, Zilembo N, Haspinger ER, et al. Targeted therapy-induced diarrhea: A review of the literature. Crit Rev Oncol Hematol. 2014;90(2):165–179. doi: 10.1016/j.critrevonc.2013.11.008
  43. Secombe KR, Van Sebille YZA, Mayo BJ, et al. Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: potential role of the microbiome. Integr Cancer Ther. 2020;19:1534735420928493. doi: 10.1177/1534735420928493
  44. Yang JC, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):729–736. doi: 10.1586/era.13.31
  45. Peterson ME. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer. 2013;21(8):2341–2349. doi: 10.1007/s00520-013-1826-3
  46. Chan DLH, Segelov E, Wong RS, et al. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev. 2017;6(6):CD007047. doi: 10.1002/14651858.CD007047.pub2
  47. Sim EH, Yang IA, Wood-Baker R, et al. Gefitinib for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2018;1(1):CD006847. doi: 10.1002/14651858.CD006847.pub2
  48. Greenhalgh J, Boland A, Bates V, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2021;3(3):CD010383. doi: 10.1002/14651858.CD010383.pub3
  49. Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3342–3350. doi: 10.1200/JCO.2012.46.1764
  50. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222. doi: 10.1016/S1470-2045(13)70604-1
  51. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004;22(5):777–784. doi: 10.1200/JCO.2004.08.001
  52. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004;22(5):785–794. doi: 10.1200/JCO.2004.07.215
  53. Wu YL, Saijo N, Thongprasert S, et al. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer. 2017;104:119–125. doi: 10.1016/j.lungcan.2016.11.022
  54. Wu YL, Fukuoka M, Mok TS, et al. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer. 2013;81(2):280–287. doi: 10.1016/j.lungcan.2013.03.004
  55. Thongprasert S, Duffield E, Saijo N, et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011;6(11):1872–1880. doi: 10.1097/JTO.0b013e31822adaf7
  56. Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017;28(10):2443–2450. doi: 10.1093/annonc/mdx359
  57. Chen YM, Tsai CM, Fan WC, et al. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older. J Thorac Oncol. 2012;7(2):412–418. doi: 10.1097/JTO.0b013e31823a39e8
  58. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. doi: 10.1016/S1470-2045(11)70393-X
  59. Heigener DF, Deppermann KM, Pawel JV, et al. Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer. Lung Cancer. 2014;84(1):62–66. doi: 10.1016/j.lungcan.2014.01.024
  60. Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012;13(11):1161–1170. doi: 10.1016/S1470-2045(12)70412-6
  61. Lee A, Arasaratnam M, Chan DLH, et al. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Cochrane Database Syst Rev. 2020;5(5):CD013238. doi: 10.1002/14651858.CD013238.pub2
  62. Jiao J, Li C, Yu G, et al. Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites. World J Surg Oncol. 2020;18(1):180. doi: 10.1186/s12957-020-01956-y
  63. Baratelli C, Zichi C, Di Maio M, et al. A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. Crit Rev Oncol Hematol. 2018;122:21–29. doi: 10.1016/j.critrevonc.2017.12.010
  64. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–iv142. doi: 10.1093/annonc/mdx225
  65. Loranskaya ID. Diareya pri zabolevaniyakh organov pishchevareniya [Internet]. Lechashchiy vrach. 2007. Available from: https://www.lvrach.ru/2007/06/4535302. Accessed: Aug 13, 2021. (In Russ.)
  66. Goldkuhle M, Dimaki M, Gartlehner G, et al. Nivolumab for adults with Hodgkin’s lymphoma (a rapid review using the software RobotReviewer). Cochrane Database Syst Rev. 2018;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2
  67. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J Clin Oncol. 2018;36(14):1428–1439. doi: 10.1200/JCO.2017.76.0793
  68. Slangen RM, van den Eertwegh AJ, van Bodegraven AA, de Boer NKh. Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab. World J Gastrointest Pharmacol Ther. 2013;4(3):80–82. doi: 10.4292/wjgpt.v4.i3.80
  69. De Felice KM, Gupta A, Rakshit S, et al. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015;25(4):321–327. doi: 10.1097/CMR.0000000000000165
  70. Mocellin S, Goodwin A, Pasquali S. Risk-reducing medications for primary breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2019;4(4):CD012191. doi: 10.1002/14651858.CD012191.pub2
  71. Lee HY, Lee YH, Kim MJ, Kim HK. Secondary prophylaxis of docetaxel induced diarrhea with loperamide: case report. J Korean Med Sci. 2013;28(10):1549–1551. doi: 10.3346/jkms.2013.28.10.1549
  72. Lawrie TA, Green JT, Beresford M, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev. 2018;1(1):CD012529. doi: 10.1002/14651858.CD012529.pub2

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Sychev D., Ostroumova O., Ziganshina L., Filippova A., 2021

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.